CVE:AQS Aequus Pharmaceuticals (AQS) Stock Price, News & Analysis C$0.0050 0.00 (-37.50%) As of 04/25/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsInsider TradesBuy This Stock About Aequus Pharmaceuticals Stock (CVE:AQS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aequus Pharmaceuticals alerts:Sign Up Key Stats Today's RangeC$0.01▼C$0.0150-Day RangeC$0.01▼C$0.0152-Week RangeC$0.01▼C$0.04Volume100,000 shsAverage Volume162,442 shsMarket CapitalizationC$663.15 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease. The company was incorporated in 2013 and is headquartered in Vancouver, Canada. Read More Receive AQS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aequus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AQS Stock News HeadlinesAequus Pharmaceuticals: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (AQS)January 22, 2025 | theglobeandmail.comAequus Pharmaceuticals Reports Revenue Growth Amid RestructuringNovember 9, 2024 | markets.businessinsider.comI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong. | Porter & Company (Ad)Aequus Pharmaceuticals Inc. (AQSZF)September 5, 2024 | finance.yahoo.comAequus Pharmaceuticals Inc (AQS)August 3, 2024 | investing.comClosing Bell: Aequus Pharmaceuticals Inc down on Friday (AQS)July 23, 2024 | theglobeandmail.comAequus Pharmaceuticals Full Year 2023 Earnings: CA$0.022 loss per share (vs CA$0.024 loss in FY 2022)May 2, 2024 | finance.yahoo.comAQS:CA Aequus Pharmaceuticals Inc.April 19, 2024 | seekingalpha.comSee More Headlines AQS Stock Analysis - Frequently Asked Questions How have AQS shares performed this year? Aequus Pharmaceuticals' stock was trading at C$0.01 at the beginning of the year. Since then, AQS shares have decreased by 50.0% and is now trading at C$0.01. How do I buy shares of Aequus Pharmaceuticals? Shares of AQS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Aequus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aequus Pharmaceuticals investors own include Growlife (PHOT), Unrivaled Brands (TRTC), Acorn Energy (ACFN), Crown Castle (CCI), LiCo Energy Metals (LIC), Marijuana Company of America (MCOA) and Rogers (ROG). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:AQS CIKN/A Webwww.aequuspharma.ca Phone+1-604-3367906FaxN/AEmployees12Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$2.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,569.60% Return on Assets-178.79% Debt Debt-to-Equity Ratio138.88 Current Ratio0.07 Quick Ratio0.46 Sales & Book Value Annual SalesC$1.17 million Price / Sales0.57 Cash FlowC$0.00 per share Price / Cash Flow5.00 Book ValueC($0.04) per share Price / Book-0.13Miscellaneous Outstanding Shares132,630,000Free FloatN/AMarket CapC$663.15 thousand OptionableNot Optionable Beta-0.02 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (CVE:AQS) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aequus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aequus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.